Chronic Refractory Cough (CRC) - Epidemiology Forecast - 2032

This ‘Chronic Refractory Cough - Epidemiology Forecast-2032' report delivers an in-depth understanding of the Chronic Refractory Cough, historical and forecasted epidemiology as well as the Chronic Refractory Cough trends in the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Chronic Refractory Cough Disease Understanding

Chronic Refractory Cough (CRC) is defined as a cough lasting more than 8 weeks despite guidelines-based treatment and which may be treated only by different medical specialties. Individuals with CRC have impaired quality of life and interruption of activities of daily living. It also results in depression and can persist for many months or years, despite systematic investigation and treatment of known causes. The infection can also be referred to as chronic cough (CC), chronic idiopathic cough (CIC), unexplained chronic cough (UCC), and cough hypersensitivity syndrome (CHS).

Recurrent incidence of CC results in CRC. The symptoms and indications of CRC are similar to those of CC. One of the first and most important symptoms that may indicate respiratory involvement is a persistent or chronic cough. Key symptoms include a dry irritating cough localized around the laryngeal region. Symptoms are not restricted to cough and can include globus, dyspnea, and dysphonia. CRC has factors in common with laryngeal hypersensitivity syndromes and chronic pain syndromes, and these similarities help to shed light on the pathophysiology of the condition.

Laryngopharyngeal reflux (LPR) is a common cause of CRC and may be present without symptoms of classic GERD, including heartburn (silent reflux). Obstructive sleep apnoea syndrome (OSAS) is also an independent risk factor for CC and a risk factor for LPR/GERD recalcitrant to medical therapy. ACE inhibitors are another common cause of CRC, which can occur spontaneously even after many years on this medication without previous problems.

CC is more prevalent in women, and there are various complications associated with it which include negative psychological, social, and physical outcomes. It causes an interruption of daily activities, social embarrassment, and physical exhaustion secondary to frequent coughing episodes.

Chronic Refractory Cough Diagnosis

CRC can be diagnosed when patients have no identified causes of CC or when the cough persists after investigation and treatment of cough-related conditions.

The diagnosis of the disease is either done by primary or secondary assessment. The initial assessment for protracted or chronic cough is intended to characterize the condition based on history, elicit any alarm symptoms or findings that may indicate a serious underlying disease, and identify whether there is a specific disease present that is associated with CC.

The first step in evaluating individuals with CRC is performing a correct and complete anamnesis, followed by a physical examination. While the second stage of investigation is considered to further characterize the condition of the disease. These include nasendoscopy and 24-hour pH monitoring. Laryngeal examination using flexible nasendoscopy identifies the presence of laryngeal lesions or abnormal motor patterns that might be contributing to the cough symptoms and laryngeal discomfort.

Some of the common tests that are performed to examine chronic cough are chest radiograph, spirometric and peak expiratory flow measurements, bronchoprovocation testing, sinus imaging, etc.

Chronic Refractory Cough Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by 12-month Prevalent Cases of Chronic Cough, Gender-specific Cases of Chronic Cough, Total Diagnosed Prevalent Cases of Chronic Refractory Cough, and Diagnosed Prevalent Cases of Chronic Cough in Idiopathic Pulmonary Fibrosis scenario of CRC in the 7MM covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Chronic Refractory Cough Detailed Epidemiology Segmentation

• In 2021, the 12-month prevalent cases of CC were estimated to be 30,625,209 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 0.4% during the study period (2019-2032).
• Among the 7MM, the United States accounted for nearly 42% of the 12-month prevalent cases of CC with 12,782,168 cases in 2021 which are expected to increase further by 2032.
• Assessments as per the analysts show that the total diagnosed prevalent cases of CRC in the 7MM were 12,250,084 cases in 2021. Among the 7MM, in 2021, the US accounted for nearly 41.7% of the total diagnosed prevalent cases of CRC. The prevalent population for CRC was derived from the prevalent patient pool of CC.
• In the US, the gender-specific cases of CC were 5,061,738 and 7,720,429 cases for males and females, respectively in the year 2021, which are expected to increase by 2032.
• Among the EU-5, Germany accounted for the highest number of total diagnosed prevalent cases of CRC (1,383,684), followed by Italy with 1,034,973 cases in 2021. In contrast, Spain accounted for the least of the total diagnosed prevalent cases of CRC in the EU-5.
• In 2021, Japan accounted for 1,812,612 cases of total diagnosed prevalent cases of CRC, which is approximately 15% of the 7MM total diagnosed prevalent cases of CRC.
• In the US, the diagnosed prevalent cases of CC in IPF were 75,537 cases in 2021 which are expected to increase by 2032.

Scope of the Report

• The report covers a descriptive overview of Chronic Refractory Cough, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden of Chronic Refractory Cough.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for the 7MM, 12-month Prevalent Cases of Chronic Cough, Gender-specific Cases of Chronic Cough, Total Diagnosed Prevalent Cases of Chronic Refractory Cough, and Diagnosed Prevalent Cases of Chronic Cough in Idiopathic Pulmonary Fibrosis.

Report Highlights

• 11-Year Forecast of Chronic Refractory Cough
• The 7MM Coverage
• 12-month Prevalent Cases of Chronic Cough
• Gender-specific Cases of Chronic Cough
• Total Diagnosed Prevalent Cases of Chronic Refractory Cough
• Diagnosed Prevalent Cases of Chronic Cough in Idiopathic Pulmonary Fibrosis

Key Questions Answered

• What are the disease risk and burdens of Chronic Refractory Cough?
• What is the historical Chronic Refractory Cough patient pool in the United States, the EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Chronic Refractory Cough at the 7MM level?
• What will be the growth opportunities across the 7MM concerning the patient population with Chronic Refractory Cough?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Chronic Refractory Cough during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to Buy

The Chronic Refractory Cough report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM Chronic Refractory Cough epidemiology forecast.
• The Chronic Refractory Cough epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.
• The Chronic Refractory Cough epidemiology model developed by the publisher is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• The EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032